Tokyo-Based EPS Responds to Growing Customer Demand for Medidata Rave in
NEW YORK & TOKYO, October 2 /CNW/ - Medidata Solutions, a global provider
of electronic clinical data capture (EDC), management and reporting solutions,
today announced the start of its ASPire to Win(TM) partnership with EPS, one
of Japan's largest contract research organizations (CRO). As the first ASPire
to Win partner in Japan, EPS can now easily incorporate Medidata Rave(R) into
their existing offerings to manage electronic clinical trial data for
biopharmaceutical and medical device companies around the world.
Established in 1991, EPS provides a full range of professional services
in clinical trials for drug development to pharmaceutical companies in Japan.
EPS selected Medidata Rave due to increased sponsor demand for the product's
robust functionality, ease-of-use and integration capabilities. By
participating in Medidata's ASPire to Win Program, a non-exclusive application
service provider (ASP) partnership and business model, EPS can offer Medidata
Rave in-house and create new services revenue around the implementation of
this industry-leading technology.
"At EPS, we have trust in Medidata due to the company's growing market
presence in Japan and globally. We respect the company's ability to support
global studies through Rave's multi-lingual capabilities and manage clinical
trial data in a single, secure and scalable system," said Hisao Imamura,
Senior Manager in the office of the president at EPS. "We look forward to
working with Medidata to provide the strongest EDC and CRO services available
to customers in the demanding Japan market."
Since the trend toward clinical research outsourcing is still new in
Japan, there are many challenges to address to meet the increasing customer
needs for both quality and quantity of services. Through implementing Medidata
Rave, EPS will accelerate their new business of global studies. Additionally,
with the greater ability to streamline clinical data collection and management
for its clients, the Rave certification will allow EPS to continue to expand
their offerings for sponsors.
"As one of Japan's largest CROs, EPS maintains a proven ability to
contribute to better pharmaceutical product development, and the company's
decision to implement Medidata Rave into their existing EDC solution will help
facilitate the constant growth of Rave in Japan - and around the globe," said
Tarek Sherif, CEO at Medidata Solutions. "We look forward to furthering the
success of EPS' new and existing customers through Medidata's ASPire to Win
EPS is a CRO (contract research organization) that operates clinical
trials precisely, rapidly and objectively. We provide a full range of
professional services in Japan, China and Southeast Asia. We are supporting
entire drug development with SMO, IT and global business. For more
information, please visit www.eps.co.jp/.
About Medidata Solutions Worldwide
Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the value of
their clinical research investments. Innovative process design, technology and
services streamline clinical trials by providing early visibility to reliable
clinical data - the lifeblood of every research organization. Working with
companies and institutions both large and small, Medidata Solutions helps
clinical researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80 countries.
Medidata Solutions brings significant value to its broad client base with deep
clinical experience and expertise in more than 20 therapeutic areas, projects
in Phase I, II, III, IV, registries and surveillance, and studies with
thousands of investigators and tens-of-thousands of subjects. For more
information, please visit www.mdsol.com.
For further information:
For further information: Lois Paul & Partners Susan Lombardo,